Press Releases

The current edition of the US-American trade magazine "Pharma Tech Outlook" (www.pharmatechoutlook.com) names Lödige Process Technology among its "Top 10 Pharma Tech Solution Providers in Europe". For this annual overview, the editorial team selects the ten most important European solution providers for pharmaceutical technology. According to the jury, the label is awarded to "the pioneers in this space who are in the frontline in providing some unparal

Jazz Pharmaceuticals plc and GW Pharmaceuticals plc announced the companies have entered into a definitive agreement for Jazz to acquire GW for $220.00 per American Depositary Share (ADS), in the form of $200.00 in cash and $20.00 in Jazz ordinary shares, for a total consideration of $7.2 billion, or $6.7 billion net of GW cash. The transaction, which has been unanimously approved by the Boards of Directors of both companies, is expected to close in the second quarter of 2021. Upon

Avid Bioservices, Inc. and Humanigen, Inc. announced that they have entered into a manufacturing services agreement to expand production capacity for lenzilumab™, Humanigen’s therapeutic candidate in development for COVID-19. Lenzilumab is an anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody designed to prevent and treat an immune hyper-response called “cytokine storm” associated with COVID-19. Humanigen has completed enrollment o

The international specialty glass group SCHOTT is continuing its positive development and is setting the course for a new phase of growth with its ongoing investment program. Despite a generally weak economic environment due to the Coronavirus pandemic, SCHOTT continued to develop its key financial figures positively in the 2020 fiscal year or maintained them at the good level in its key markets including India. "Even in currently difficult economic times, we have stayed on cou

Syntegon Technology recently installed the first fully validated visual inspection system utilizing Artificial Intelligence (AI) in an automated inspection machine. The installation constitutes a major step in the company’s sustained effort to introduce AI to pharmaceutical visual inspection, thereby exploring largely uncharted territory in the industry. “We are proud to announce this important move, which is the joint result of long-standing visual inspection expertise, solid sof

A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc.  announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic investment of $50 million in Coherus pursuant to the terms of the definitive stock purchase agreement.   “We view our collaboration with Coherus as a strategic long-term partnership for the development and commercialization of toripalimab and

X-Chem, Inc., a global leader in DNA-Encoded Library (DEL) technology to identify novel drug leads, announced that it has entered into a research collaboration and license agreement with Genentech, a member of the Roche Group. The goal of the collaboration is to discover and develop novel small molecule treatments in oncology. Under the terms of the agreement, X-Chem will deploy its proprietary DEL platform to identify novel drug-like leads against multiple oncology targets of inter

Health industry digitalization is one of the highest priorities in the healthcare sector these times. In perspective, it improves current living standards with quicker and easier access to help. The Healthcare Automation and Digitalization Congress business program will cover digital trends in the healthcare industry. The Congress will take place in Zurich, Switzerland on the 27th– 28th of September, 2021. Growth of pharmaceutical costs, poorly integrated doctor-patient intera

SQZ Biotechnologies, a cell therapy company developing novel treatments for multiple therapeutic areas, announced that the company’s Investigational New Drug (IND) application for SQZTM Activating Antigen Carriers (SQZ AACs) in HPV+ tumors was cleared by the U.S. Food and Drug Administration (FDA). The clinical trial will investigate SQZ-AAC-HPV, a cell therapy candidate generated from red blood cells (RBCs) engineered with tumor-specific antigen to treat HPV+ tumors. This trial, SQZ-AA

Junshi Biosciences, an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced a collaboration with Coherus BioSciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences’ anti-PD-1 antibody, in the United States and Canada. Under the terms of the agreement, Junshi Biosciences will receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and mil